Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Nov 2016
At a glance
- Drugs Lapatinib (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 23 Nov 2016 Planned primary completion date changed from 1 Mar 2019 to 1 Jun 2019.
- 24 May 2016 Status changed from recruiting to active, no longer recruiting.